Ocugen: A Retinal Disease Juggernaut In The Making (NASDAQ:OCGN)

Group 1 - The author, Sean Daly, specializes in ETFs, biotech, and FINTECH solutions within the banking sector [1] - He has a strong academic background, having taught international finance and financial risk management at Pace University and served as a visiting lecturer at Princeton University [1] - Daly's research interests include diverse topics such as Chinese urbanization, multilateral currency swap arrangements, energy geopolitics, and Asia's sovereign wealth funds [1] Group 2 - The author has a beneficial long position in the shares of OCGN, indicating a personal investment interest [2] - The article reflects the author's own opinions and is not influenced by compensation from any company mentioned [2]